Salad lovers have no fear! Safe lettuce is here! The lettuce that made over 170 people sick is no longer available for sale.
Last month, the Center for Disease Control (CDC) released a report linking the recent E. coli outbreak to romaine lettuce. Both the Food and Drug Administration and CDC announced this week that the infected lettuce is no longer a threat.
“It is unlikely that any romaine lettuce from the Yuma growing region is still available in stores or restaurants due to its 21-day shelf life,” the CDC said in a statement. The FDA made their announcement on Twitter.
UPDATE on Romaine Lettuce: It is highly unlikely that product from the Yuma growing region is still in the supply chain. Consumers can be confident that romaine currently available for purchase is not part of the investigation. FDA continues to investigate https://t.co/PSjH1LztER pic.twitter.com/cHvhkmZmuB
— U.S. FDA (@US_FDA) May 17, 2018
As of May 16, 2018, 172 people across 32 have fallen ill from the E. coli outbreak, and one death was reported from California. According to the CDC, almost half of those who were sickened were hospitalized.
While the culprit lettuce is no longer available, consumers are advised to take action if they exhibit symptoms of an E. coli infection. On average, people become sick three to four days after being infected with E. coli. Such symptoms include diarrhea, abdominal cramping, nausea, and vomiting.
Are you looking for digital journalism training and experience? Are you a journalism major who wants to take your career to the next level? CMN’s Digital Journalism course gives you real-time experience, intense feedback on your writing, exposure to journalism influencers and mentors, and a great place to display your work. You can get academic credit too. Check out the Digital Journalism Course here.
Sign up for the Morning Scoop
Former Astronaut Mark Kelly Will Run for Senate in 2020
If elected in 2020, Kelly will become fourth-ever American astronaut elected to Congress.
Senator Elizabeth Warren Wants to Create a Public Option for Generic Drugs
The Massachusetts senator wants to take on big pharma.